Clinical Trial Update: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection [Phase 3]

View source ↗

Summary

Phase 3 trial update showing efficacy and safety of the ledipasvir/sofosbuvir fixed-dose combination in chronic genotype 1 hepatitis C infection; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir/Sofosbuvir fixed-dose combination (Ledipasvir + Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic HCV Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-12-28